Rx Propellant

Rx Propellant At Rx Propellant, an Actis platform, we are dedicated to building world-class life sciences clusters in India.

Our vision is to create state-of-the-art campuses enabling seamless integration of diverse operations from concept to commercialization. The Rx Propellant leadership with 30+ years combined experience in real estate has been instrumental in the conceptualization and development of Genome Valley (GV), Hyderabad as a part of the teams at E&Y and Alexandria Real Estate Inc. What we do
We build world-

class Lifesciences clusters by leveraging our expertise in real estate and deep understanding of the Lifesciences domain. We complement real estate with a range of ecosystem support services.

• Real Estate: We build state-of-the-art infrastructure tailored to address the needs of our partners. We have five projects in Genome Valley, Hyderabad
- Touchstone Square
- ARX
- Innopolis
- Genopolis
- Nextopolis
Additionally, we have a project in Bengaluru called BLR District and two upcoming projects in Pune and Ahmedabad. Our suite of real estate services ranges from development, financing, acquisition, leasing, asset, and facility management.

• Ecosystem Services
- GV Connect: India’s first cluster development enterprise in GV dedicated to promoting the growth of life sciences hubs in India
- GVALS: Genome Valley Academy of Life Sciences (GVALS) is an industry-led skill development initiative that helps bridge the academia-industry gap in Lifesciences
- CoLabs: CoLabs is a novel concept of flexi labspaces for incubating early-stage companies

Website: https://rxpropellant.in/
Contact: [email protected]

    is a growing and very promising, area of   Season 2 | episode 1 of RX Propellant's   series,   Feat: Anu Acharya - F...
30/01/2023

is a growing and very promising, area of Season 2 | episode 1 of RX Propellant's series,

Feat: Anu Acharya - Founder and CEO of Ocimum Bio Solutions and Mapmygenome

See the video here:

Rx Propellant’s Podcast Series, Voices of Science – Echoes from the - Season 2 | Episode 1. Hosted by Satesh C. RagooWe chat with Ms An...

   Online Panel DiscussionLife science infrastructure in Bengaluru: Building capacities for start-ups & scale-upsDate/Ti...
09/09/2022



Online Panel Discussion

Life science infrastructure in Bengaluru: Building capacities for start-ups & scale-ups

Date/Time 🗓️: 23 September | 3:30PM-4:30PM IST

Featured Panelists:
Dr Ezhil Subbian - CEO | String Bio Private Limited
Dr. Vinay Babu - Founder & MD | BIONEEDS INDIA PRIVATE LIMITED
Dr Jitendra Kumar - MD | Bioinnovation Centre, Bangalore
Dr Prabhakar Kulkarni Ph.D - CEO | NeoDx Biotech Labs
Mr Krishnan G S - President | ABLE - Association of Biotechnology Led Enterprises
Dr Ketki Tulpule, PhD | Vice President International Business Development & Strategy | Rx Propellant

Moderated by Mr Satesh Ragoo - Senior Manager, Marketing | Rx Propellant

Register here: https://bit.ly/3BrON45

The discussion will explore the various needs of the life science community in setting and scaling-up successful enterprises in .

An Rx Propellant initiative in collaboration with ABLE - Association of Biotechnology Led Enterprises and K-tech Biotechnology Facilitation Cell Karnataka Innovation and Technology Society

  in    from our   togetherWe are truly grateful to the teams from Curia (formerly AMRI), DFE Pharma, Syngene Internatio...
07/09/2022

in

from our together

We are truly grateful to the teams from Curia (formerly AMRI), DFE Pharma, Syngene International Limited and Yapan Bio for graciously participating in the Ganesh Utsav festivities in Genome Valley - R&D District, organised by GV Connect from 31st August to 6th September 2022.

Here’s a glimpse of the 7-day long celebrations of the auspicious event.

Thanks to all the persons and teams involved in organising this event and making it a success!

Proud moment for Genome Valley Cluster as Bharat Biotech's intranasal Covid vaccine gets DCGI (Drugs Controller General ...
06/09/2022

Proud moment for Genome Valley Cluster as Bharat Biotech's intranasal Covid vaccine gets DCGI (Drugs Controller General of India) approval for restricted emergency use. This based firm pioneers India's first nasal vaccine for Covid-19.

Read more: https://lnkd.in/gvvedi3h

The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there are no side effects or adverse reactions reported so far, PTI reported.

Address

Hyderabad
500034

Alerts

Be the first to know and let us send you an email when Rx Propellant posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Rx Propellant:

Share